Search

Your search keyword '"Thanopoulos, B.D."' showing total 8 results
Start Over Author "Thanopoulos, B.D."
8 results on '"Thanopoulos, B.D."'

2. Catheter closure of perimembranous/membranous ventricular septal defects using the amplatzer occluder device

Author

Thanopoulos, B.D.

Subjects
Medical equipment -- Usage -- Research, Catheterization -- Usage -- Research, Ventricular septal defects -- Care and treatment -- Research, Physiological apparatus -- Usage -- Research, Health, Care and treatment, Usage, Research
Abstract

Abstract. Perimembranous ventricular septal effects (PMVSDs) are the most common congenital cardiac defects of clinical importance. During the last decade, transcatheter closure of PMVSDs has been attempted using various occluders [...]

Published
2005

4. Transcatheter closure of high pulmonary artery pressure persistent ductus arteriosus with the Amplatzer muscular ventricular septal defect occluder. (Congenital Heart Disease)

Author

Thanopoulos, B.D., Tsaousis, G.S., Djukic, M., Hakim, F. Al, Eleftherakis, N.G., and Simeunovic, S.D.

Subjects
Ventricular septal defects -- Care and treatment, Patent ductus arteriosus -- Care and treatment, Health, Care and treatment
Abstract

Background: The design of devices currently used for closure of persistent ductus arteriosus (PDA) with high pulmonary artery pressure is not ideal and there is a risk of embolisation into [...]

Published
2002

6. Catheter Closure of Congenital/Acquired Muscular VSDs and Perimembranous VSDs Using the Amplatzer Devices

Author

Thanopoulos, B.D. Karanassios, E. Tsaousis, G. Papadopoulos, G.S. Stefanadis, C.

Abstract

Over the past 10 years a variety of occluding devices has been used for transcatheter closure of ventricular septal defects (VSDs), but none has gained wide acceptance. This article presents the experience of transcatheter closure of muscular and perimembranous VSDs in 22 and 13 patients, respectively, with the new Amplatzer VSD occluders. Overall total occlusion was achieved in 95% and 92.3% of patients with muscular and perimembranous VSDs, respectively. The main complication was embolization of the device in 1/13 (7.6%) patients with perimembranous VSDs. Transcatheter closure of VSDs using the Amplatzer VSD occluders appears to be a safe and effective alternative to the standard surgical treatment.

Published
2003

7. Transcatheter closure of perimebranous ventricular septal defects with the Amplatzer asymmetric ventricular septal defect occulder: preliminary experience in children.

Author

Thanopoulos, B.D., Tsaousis, G.S., Karanasios, E., Eleftherakis, N.G., and Paphitis, C.

Subjects
*CONGENITAL heart disease in children, *VENTRICULAR septal defects
Abstract

Objective: To close perimembranous ventricular septal defects (PMVSDs) in children with the new Amplatzer asymmetric ventricular septal defect occluder (AAVSDO). Patients and design: 10 children, aged 1.5-12 years, with PMVSDs underwent transcatheter closure with the AAVSDO. The device consists of two low profile disks made of Nitinol wire mesh with a 1.5 mm connecting waist. The left disk is 5 mm towards the apex and only 0.5 mm towards the aortic valve. The right disk is 4 mm larger than the waist. The prosthesis diameter was chosen to be 1-2 mm larger than the largest diameter of the defect (determined by transoesophageal echocardiography and angled angiocardiography). A 7-8 French gauge sheath was used to deliver the AAVSDO. Results: The,PMVSD diameter ranged from 2-8 mm. The device diameter ranged from 4-8 mm. After deployment of the prosthesis there was no residual shunt in 9 of 10 patients (90%). In one patient there was a trivial residual shunt that disappeared at the three month follow up. Three patients developed transient complete left bundle branch block. No other complications were observed. Conclusions: The AAVSDO appears to be a promising device for transcatheter closure of PMVSDs in children. Further studies are required to document its efficacy, safety, and long term results in a larger patient population. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

8. Stent treatment for coarctation of the aorta: intermediate term follow up and technical considerations

Author

Thanopoulos, B.D., Konstadopoulou, G.N., Tsaousis, G.S., Hadjinikolaou, L., Triposkiadis, F., and Spirou, P.

Abstract

ObjectiveTo report the initial and intermediate term results of stent implantation in children with coarctation of the aorta.Patients and design17 patients with coarctation of the aorta underwent stent implantation (median age 11 years, range 0.4-15 years); six were treated for isolated coarctation, nine for recurrent coarctation (five after surgical repair and four after balloon dilatation), and two for complex long segment coarctation.InterventionsThe procedure was guided by a second catheter placed transseptally in the left ventricle or the aorta proximal to the coarctation site, for angiographic and haemodynamic monitoring during the procedure. Twenty two stents were implanted in 17 patients. One of the patients with long segment coarctation received four stents and the other three. Palmaz 4014 stents were placed in 11 patients, Palmaz 308 in five, and Palmaz 154 in one.ResultsImmediately after stent implantation the peak systolic gradient (mean (SD)) fell from 50.0 (24.5) to 2.1 (2.4) mm Hg (p < 0.05). The diameter of the stenotic lesion increased from 5.1 (1.5) mm to 13.9 (2.4) mm (p < 0.05). There were no deaths or procedure related complications. At a median follow up of 33 months, no cases of recoarctation were identified, either clinically (0/17; 0%, 95% confidence interval (CI) 0% to 19%) or angiographically (0/13; 0%, 95% CI 0% to 25%).ConclusionsStent implantation for the treatment of coarctation of the aorta appears to have very low morbidity and mortality, and reasonable intermediate term results. Long term freedom from recoarctation using this method remains to be determined in comparison with simple balloon dilatation.

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results